Amgen Inc.

Medimmune Limited

Steven Roy Coats

Murray O Robinson

Michael Brian Bass

Changshou Gao

Melissa Marie Damschroder

John H Li

Andy Q Yuan

Godfrey Rainey

Nazzareno Dimasi

Cuihua Gao

Srinath Kasturirangan

Ryan Fleming

Binyam Bezabeh

Dorin Toader

Lakshmaiah Gingipalli

Fengjiang Wang

Andy Qingan Yuan

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

Disclosed are nucleic acid molecules encoding cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Antibodies to cyclin E2 protein

Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Cyclin E genes and proteins

Growing community of inventors

Camarillo, CA, United States of America

Steven Roy Coats